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Abstract
Objective: During the last 10 years we have experienced an increasing number of referrals due to hyperferritinemia. This is
probably due to increased awareness of hereditary hemochromatosis, and the availability of a genetic test for this condition.
Most of these referred patients were over-weight middle-aged men with elevated ferritin levels, but without the
hemochromatosis-predisposing gene mutations. We evaluated the relationship between hyperferritinemia and the
metabolic syndrome in 40 patients.
Methods: Forty consecutive patients referred for hyperferritinemia were investigated. The examination programme
included medical history, clinical investigation and venous blood samples drawn after an overnight fast. This resulted in 34
patients with unexplained hyperferritinemia, which were further examined. Liver biopsy was successfully performed in 29
subjects. Liver iron stores were assessed morphologically, and by quantitative phlebotomy in 16 patients.
Results: The majority of the patients had markers of the metabolic syndrome, and 18 patients (52%) fulfilled the IDF-criteria
for the metabolic syndrome. Mean body mass index was elevated (28,864,2), mean diastolic blood pressure was
88,5610,5 mmHg, and mean fasting insulin C-peptide 14986539 pmol/l. Liver histology showed steatosis and nuclear
glycogen inclusions in most patients (19 out of 29). Only four patients had increased iron stores by histology, of which two
could be explained by alcohol consumption. Fourteen of 16 patients normalized ferritin levels after phlebotomy of a
cumulative blood amount corresponding to normal iron stores. Ferritin levels were significantly related to insulin C-peptide
level (p,0.002) and age (p,0.002).
Conclusion: The present results suggest that liver steatosis and insulin resistance but not increased iron load is frequently
seen in patients referred for suspected hemochromatosis on the basis of hyperferritinemia. The ferritin level seems to be
positively associated to insulin resistance.
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Introduction
Hemochromatosis is a disease with vague symptoms, serious
complications and an effective treatment. Since the genetic test for
hereditary hemochromatosis became available in 1996, focus on the
disease has increased [1]. Serum-ferritin is frequently used as a first
line blood test when iron overload is suspected. However, ferritin is
also elevated in inflammatory states and malignant diseases [2].
The hemochromatosis-associated genotype (homozygous
C282Y mutation of the hfe- gene) is found in about 85% of
patients with hereditary hemochromatosis [3]. The hfe-gene codes
for the HFE-protein, which plays an important role in iron
absorption in enterocytes [4].
A possible link between hepatic iron-overload and insulin
resistance has been reported [5–7], and an association of non-
alcoholic steatohepatitis (NASH) and insulin resistance has also
been shown [8]. In some patients with NASH ferritin was elevated.
Since 1996 we have experienced an increasing number of
referrals from general practitioners of patients with hyperferriti-
nemia. Many patients were overweight, middle-aged men with
vague symptoms such as tiredness, fatigue, myalgia and arthralgia.
Liver transaminases, especially alanine amino transferase (ALT),
were often elevated. Transferrin saturation was within the
reference range and the HFE gene mutation was negative. Liver
biopsy often showed steatosis and nuclear glycogen inclusions,
which is a frequent finding in prediabetes and diabetes mellitus
type 2 (DM2) [9]. Usually there were no definite signs of iron
overload or other pathology.
We have examined the relationship between hyperferritinemia,
iron-load and insulin resistance in patients referred for elevated
ferritin levels and suspicion of hemochromatosis. Patients were
examined and treated according to best practice.
Methods
Patients
During 2001 40 patients were referred to the hematology clinic
at Aalesund Hospital due to elevated ferritin levels and suspicion of
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hemochromatosis. This is an observational study with retrospec-
tive analysis of the results of the examination programme. All
patients gave oral consent to the examination programme. Due to
the retrospective observational nature of the study, the Regional
ethics committee of Mid-Norway had no comment to the study,
and as the examinations themselves were part of a clinical quality
assurance program, they did not need formal approval from the
ethics committee. However, all patients gave oral consent to the
use of clinical data for research purposes.
Five patients had hereditary hemochromatosis and one had
hemosiderosis secondary to excessive iron intake. Hence 34
patients (33males, 1 female) had no hfe-mutation known to
predispose for hemochromatosis (neither homozygous for C282Y
nor compound heterozygous, i.e. heterozygous for both C282Y
and H63D) and was further examined to reveal other causes for
hyperferritinemia.
Examinations
A structured examination programme was performed including
medical history, clinical examination, laboratory tests and liver
biopsy. Reason for taking liver biopsy was hyperferritinemia/
elevated liver transaminases where examinations so far had not
given any explanation for the deviations. Examinations did not
deviate from what is usually recommended for follow-up of such
patients. The HUNT-study [10] was used as reference population
regarding BMI (women; 26.4 kg/m2, men; 26.5 kg/m2), waist-hip
ratio (women; 0.7760.06, men; 0.8960.06), systolic blood
pressure (women; 136.8 mmHg, men; 140.1 mmHg) and diastolic
blood pressure (women; 78.8 mmHg, men; 81.9 mmHg).
Laboratory tests
Venous blood samples were drawn after overnight fast.
S-iron (reference values, women; 11–23 mmol/l, men; 14–
29 mmol) was analysed using Colorimetric assay (CFAS-Roche,
Mannheim, Germany). Serum-glucose (reference value 3.6–
5.8 mmol/l), aspartate amino tranferase (AST) (reference values,
women; ,35 U/l, men; ,50 U/l), alanine amino transferase
(ALT) (reference values, women; ,35 U/l, men; ,50 U) were
measured by UV-test (CFAS-Roche, Mannheim, Germany). C-
reactive protein (CRP) was measured by a turbidimetric method
(CFAS-Roche, reference value ,6 mg/l). Hemoglobin A1C
(HbA1C) (reference value, 3.5–6.5%) used ion-change-chroma-
tography (HPLC-Biorad Variant Hb testing system, Marnes-La-
Cocuette, France). Ferritin (reference values, women; 10–250 mg/
l, men; 20–250 mg/l) and total iron binding capacity (TIBC)(re-
ference value 46–80 mmol/l) were analyzed by nephelometry
(Dade Behring. Marburg, Germany). Transferrin saturation
(%) = s-iron/TIBCx100 (reference value, 15–45%). Fasting insulin
C-peptide (reference value 240–720 pmol/l) was analysed by
chemiluminescence method (DPC-immulite. Liamberis, Gwy-
nodd, LL55 4EL, UK). HFE mutation was analyzed measuring
fragment-length polymorphisms by PCR [1].
Liver biopsies were ultrasound-guided with 18-Gauge needles.
Iron content was evaluated according to Rowe [11]: Grade 0–1 is
within normal limits, and grades 2+ to 4+ represent distinct iron
increase (70–850 mmol/g dry weight).
Phlebotomy
Iron stores were also estimated by quantitative phlebotomy in
16 patients. One gram of hemoglobin contains 3.4 mg iron, and
the amount of iron removed by phlebotomy can thus be calculated
[12–13]. The normal amount of storage iron in males, measured
by quantitative phlebotomy, has been shown to be about 750 mg
[14–15].
Definitions
There have been several definitions of the metabolic syndrome
(WHO 1999/NCEP 2001)[16–17]. We used the recent simplified
definition recommended by the International Diabetes Federation
(IDF), which emphasizes waist circumference (women; .80 cm,
men; .94 cm) in addition to minimum 2 of the following criteria:
HDL-cholesterol ,1.03 mmol/l (men), blood pressure .130/
85 mmHg, triglycerides .1.7 mmol/l, or fasting blood glucose
.5.6 mmol/l [18].
Statistical analyses
Normal distribution of data was verified by normality plots. All
normally distributed measurements are presented as mean and
standard deviations (SD), otherwise median and range were used.
Comparisons of normal distributed parameters were done by t-
tests. Univariate and multiple forward linear regression analyses
were used to investigate relations between s-ferritin and other
variables. Logaritmic transformation of s-transferrin was used to
obtain normal distribution. All tests were 2-sided, and a p-value
,0.05 was considered significant. No adjustments for multiple
testing were performed. All analyses were performed with SPSS
13.0 (SPSS Inc, USA).
Role of funding source
The funding source had no involvment in the conduction of the
study.
Results
The mean age was 53 (12.6) years.
Twenty-three percent reported DM2 among relatives, and 23%
also reported some kind of iron-overload-related problem in the
family. Fourteen percent knew about relatives with some kind of
malignant liver disease (table 1).
Symptoms reported by the patients were vague. Fifty-eight
percent reported fatigue and 17% arthralgia/myalgia.
Seventeen patients (50%) were without any medication. Most used
medicines were betablockers (7 patients), calcium-channel blockers (5
patients), ACE-inhibitors (4 patients) and metformin (4 patients).
TSH, CRP, Sedimentation rate (SR), s-electrophoresis and
transferrin saturation were all within reference limits (Table 2).
Table 1. Demographic and clinical characteristics of the
study population (n = 34).
Parameters Number (%)
Male 33 (97)
Age (mean/range) 53/28–77
Hypertension 12 (35)
Type 2 diabetes 4 (12)
Gout 3 (9)
Coronary artery disease 2 (6)
Hyperlipidemia 2 (6)
Smokers 6 (17)
No alcohol consumption 12 (35)
Minimal alcohol consumption 20 (59)
Moderate alcohol consumption (,60 g/week) 2 (6)
BMI.30 16 (47)
doi:10.1371/journal.pone.0003547.t001
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Mean values for body mass index, waist circumference, waist/
hip ratio and diastolic blood pressure were above cutoff values set
by IDF regarding criteria for the metabolic syndrome.
Thirty-two out of 34 patients (94%) had elevated insulin C-
peptide indicating hyperinsulinemia/insulin resistance.
Mean glucose was slightly elevated (6.4162.2 mmol/l), s-
triglyceride was in upper normal range, mean HDL-cholesterol
was in lower normal range, and mean ALT was elevated.
Hfe- mutation analyses showed that 22 patients were heterozy-
gous for C282Y, and twelve had neither C282Y nor H63D. There
were no compound heterozygotes.
None of the present genetic combinations are known to
predispose for iron overload, although heterozygous C282Y has
been associated with elevated serum iron markers [19].
Liver histology is reported in table 3.
The majority of patients had liver steatosis and nuclear glycogen
inclusions. Hemosiderin was within normal limits in 86% of the
patients. The one patient with hemosiderin content grade 3 was
diagnosed with steatohepatitis and surplus alcohol consumption
(carbohydrate deficient transferrin.5%). The other patient with
alcoholic steatohepatitis had also cirrhosis and iron storage grade 2
and had earlier suffered from heavy alcohol intake. Two other
patients had microscopic sign of iron overload (grade 2), without
any other obvious pathology. However the amount and distribu-
tion was not typical for hemochromatosis (not hepatocytic).
Sixteen patients were offered phlebotomy due to symptoms
described earlier. Mean volume of whole blood needed for
reaching low normal ferritin level (,100 mg/l) was 2500 ml
(1300 ml–4450 ml). Accordingly approximately 1150 mg iron was
removed for reduction of s-ferritin to low normal levels.
In univariate linear regression analysis log s-ferritin was
significantly related to age (p,0.002) and insulin C-peptide
(p,0.002). These parameters were also significantly related to s-
ferritin in multivariate regression analysis (p,0.002) (Fig. 1 and 2).
There was no significant relation between s-ferritin and transferrin
saturation, number of phlebotomies required to normalize s-
ferritin, ALT, LDL-cholesterol, HDL-cholesterol, trigyserides,
diastolic blood pressure or BMI.
Eighteen of thirty-four (52%) patients fulfilled the IDF-criteria.
In the 18 men fulfilling the criteria relative to the other male
patients median ferritin was 603 mg/l (379–1300) compared to
515 mg/l (283–871) (p = 0.05), transferrin saturation was 36%
compared to 44% (p,0.05) and mean insulin C-peptide was
1732 pmol/l compared to 1162 pmol/l (p = 0.001).
All liver biopsies showed steatosis in patients fulfilling the IDF-
criteria, with only one showing an iron content corresponding to
grade 2, the rest grade 0–1 (normal).
Discussion
Hepatic iron overload was present in only 4 patients (4/29).
These had also slightly elevated transferrin saturation. In two of
them increased iron stores were explained by alcohol consump-
tion. Liver histology, transferrin saturation, and number of
phlebotomies needed to normalize s-ferritin, indicated normal
iron-load in the remaining population. There was no sign of
inflammation or malignancy. Steatohepatitis was found in three
patients. One of these was diagnosed as NASH.
Table 2. Clinical and biochemical characteristics (n = 34).
Parameter Reference values Mean Standard deviation Range
Body mass index 26.5 (men) 28.8 4.2 23–38
Waist/hip ratio 0.89 (men) 0.97 0.07 0.83–1.17
Systolic blood pressure(mmHg) 140.1 (men) 144 19 120–195
Diastolic blood pressure (mmHg) 81.9 (men) 88.5 10.5 64–114
Heart rate (beats/min) 75 13 50–116
Transferrin saturation (%) 15–45 39 10.2 12–57
Ferritin (mg/l) 20–250 665.5 369.4 283–2190
ALT (U/l) ,50 (men) 75 44.2 22–207
Triglycerides (mmol/l) 0.6–2.2 1.8 1.3 0.5–6.5
LDL-cholesterol (mmol/l) 1.7–5.4 (men) 3.8 1.1 1.2–6.1
HDL-cholesterol (mmol/l) 0.80–2.00 (men) 1.3 0.3 0.72–2.21
HbA1C (%) 3.5–6.5 5.8 1.26 4.5–9.2
Insulin C-peptide (pmol/l) 240–720 1498 539 503–2988
Fasting glucose (mmol/l) 3.6–5.8 6.4 2.29 4.3–14.7
ALT = alanine amino transferase.
doi:10.1371/journal.pone.0003547.t002
Table 3. Liver histology (n = 29).
Histologic findings Number (%)
Normal 1 (3)
Nuclear glycogen inclusions 17 (59)
Steatosis 19 (66)
Cirrhosis (micronodular) 1 (3)
Non alcoholic steatohepatitis 1 (3)
Alcoholic steatohepatitis 2 (6)
Hemosiderin grade* 0 15 (51)
Hemosiderin grade 1 10 (34)
Hemosiderin grade 2 3 (10)
Hemosiderin grade 3 1 (3)
Hemosiderin grade 4 0 (0)
*Grading according to reference 11.
doi:10.1371/journal.pone.0003547.t003
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The majority of the study population showed markers of the
metabolic syndrome. BMI, waist-hip ratio, diastolic blood
pressure, ALT, HDL-cholesterol, fasting plasma glucose and
insulin C-peptide showed deviations typically seen in the metabolic
syndrome. Elevated insulin C-peptide levels indicate hyperinsu-
linemia and insulin resistance [20–21]. Liver histology showed
steatosis and nuclear glycogen inclusions, a typical finding in
prediabetes and DM2.
Those patients who met the criteria for the metabolic syndrome
had slightly higher ferritin and C-peptide values, but lower
transferrin saturation than the rest of the study population. One of
these had iron storage grade 2, the rest grade 0–1 in liver biopsies.
An association between hyperferritinemia and insulin resistance
in patients with different types of liver pathology has been reported
earlier. In the article by Moirand et al [5] the patients had overt
hepatic iron overload, as the median liver iron concentration was
85 mmol/g dry weight (normal ,36 mmol/g).
A relationship between non-alcoholic fatty liver disease and
insulin resistance [8], and a relationship between s-ferritin and
metabolic markers of insulin resistance but without an evaluation
of liver-histology [22–23], has previously been reported. In 1992
Dinnen et al reported that hyperferritinemia was a feature of
newly diagnosed DM2 [24], and they later presented results
indicating that DM2 did not associate with iron overload [25].
This finding has recently been confirmed by others [26].
Inflammatory mechanisms were assumed to be responsible for
the hyperferritinemia in these diabetic patients.
Our patients differed from those in the above mentioned studies
by being mostly non-diabetic, without hepatic iron overload or
other sign of liver pathology other than steatosis and nuclear
glycogen inclusions. Our patients had more expressed markers of
the metabolic syndrome than in the above studies, and mean
ferritin levels were higher. This tendency was even more striking in
the group with the metabolic syndrome. In addition ferritin levels
correlated well with fasting insulin C-peptide.
Elevated ferritin levels in our patients seemed not to be due to
iron. As elevated insulin C- peptide level is a marker of
hyperinsulinemia and indirectly insulin resistance, insulin resis-
tance might be the cause of elevated ferritin levels in our patients,
either directly or due to the steatosis itself.
Patients treated with phlebotomy experienced reduction in s-
ferritin, but after a while the level gradually increased. Those who
changed lifestyle (weight management, increased physical activity)
seemed to experience more stable s-ferritin reduction. This has to
be evaluated in further studies, and in particular correlation needs
to be observed between a durable fall in serum ferritin in response
to weight control and exercise, and a correction in insulin
resistance and reversal of fatty liver.
The finding of steatosis and nuclear glycogen inclusions further
support this theory, as it is a common finding in obesity and
prediabetes. We did not find signs of primary liver disease.
The frequency of hyperferritinemia not related to iron load is
remarkable, as is the extreme male preponderance. Insulin
resistance and metabolic syndrome is more prevalent in males
[18], but not to the extent seen in this group. Confounding factors
may have influenced patient selection, but hormonal effects and
increased iron loss in females may also have been of importance.
Selection bias on part of the referring physician is not possible to
exclude.
Possible explanations of hyperferritinemia among our patients
might be that by binding iron, ferritin protects against formation of
free hydroxyl groups, it could also be due to endothelial/
subendothelial inflammation [27–28] or simply leakage of ferritin
from hepatic cells.
The frequency of hyperferritinemia in Norwegian unselected
patient populations with insulin resistance is unknown, as are
gender difference.
The metabolic syndrome carries a well known increased risk for
cardiovascular disease [29–30]. Whether hyperferritinemia entails
an additional risk is unknown.
The greatest limitation of the study is the relatively small patient
population, and male preponderance. The strength though, is the
unselected patient population from a primary care hospital, and
the performance of liver histology from most of the patients.
In conclusion, the present study suggests that s-ferritin elevation
in our patients is a marker of the metabolic syndrome with hepatic
steatosis and insulin resistance, and not of iron overload. The
direct pathogenic mechanism, however, remains unknown.
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